	<u>,</u>			(-	
FORM PTO-14		\	ATTY. DOCKET NO. 226/104	SERIAL NO. 08/870,762	
131 07	PATENTS AND OTHER ITEMS FOR NFORMATION DISCLOSURE STAT	APPLICANT: Bradford Duft et al.			
	(Use several sheets if necessar)	(O 128 18 1	FILING DATE: June 6, 1997	GROUP: 1641	
	<del></del>	TOWN TRUE			
		U.S. PATENT DO	CUMENTS	-	
EXAMINER	1			SUP SUNG	

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING
<b>5</b> 7	AA	5,175,145	12/29/92	Cooper			DATE
<b>5</b> 7	AB	5,234,906	8/10/93	Young et al.	- REC	EIVED	
SD	AC	5,364,841	11/15/94	Cooper et al.			
SD	AD	5,656,590	8/12/97	Rink et al.	JAN	0 5 1999	

EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB CLASS YES NO

		THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
50	AE	Kolterman et al., "Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue," <u>Diabetes Care</u> 18(8):(Abstract) (1995)
<b>5</b> D	AF	Kong et al., "Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM," <u>Diabetologia</u> 40(1):82-88 (1997)
50	AG	Kong et al., "The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM," Diabetologia 41(5):577-583 (1998)
SD.	АН	Nyholm et al., "Acute effects of the human amylin analog AC137 on basal and insulin- stimulated eugycemic and hypoglycemic fuel matabolism in patients with insulin- dependent diabetes mellitus," J. Clin. Endocrinol. Metab. 81(3):1083-1089 (1998)
59	AI	metabolism," Diabetic Med. 14(2):S19-S23 (1997)
5)	AJ	Thompson et al., "Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations," <u>Diabetologia</u> 40(11):1278-1285 (1997)
5)	AK	Thompson et al., "Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes," Diabetic Med. 14(7):547-555 (1997)

		<del></del>		
EXAMINER:	67	DATE CONSIDERED:		
	59		21	June 99
			21	

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.